Trials / Terminated
TerminatedNCT00313287
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV
A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 180 (planned)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safety and efficacy of 30 mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in patients with chronic HBV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clevudine |
Timeline
- Start date
- 2003-06-01
- Completion
- 2004-11-01
- First posted
- 2006-04-12
- Last updated
- 2017-02-01
Locations
33 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00313287. Inclusion in this directory is not an endorsement.